Thus, Bin1 promoted IBD by licensing an inflammation-driven degradation of colonic barrier function, with this effect reversed by either Bin1 genetic ablation or Bin1 mAb 99D antibody treatment (Chang et al., 2012; Thomas et al., 2016; Thomas et al., 2019a). Here, BIN1 is linked to inflammatory bowel disease.